New drug hopes to slow liver damage in MASH cirrhosis patients
Disease control
Recruiting now
This study tests an experimental drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) from MASH, a fatty liver disease linked to metabolic issues. The goal is to see if the drug is safe and can help control the disease. Participants will receive either the d…
Phase: PHASE2 • Sponsor: Boston Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:16 UTC